SLR Capital Partners has a dedicated team of life science investment professionals who specialize in providing 1st lien senior secured loans to venture capital backed private and publically-traded healthcare companies. Borrowers are typically later stage drug and medical device developers, diagnostic, healthcare IT and healthcare services companies, with substantial equity invested to date. We focus on late clinical and early commercial stage companies with proprietary and innovative technologies that are backed by top-tier institutional investors, led by experienced management teams, and guided by a strong board of directors.

SLR launched its Life Science Finance platform in Q1 2014 by hiring the leader of GE Capital’s life science finance business. One year later, SLR added the core investment team that had worked with the founder since 2003 at GE Capital. SLR's Life Science investment team is now comprised of a core group of experienced professionals with deep industry expertise who have worked together for over 22 years.

From inception, the team has invested $4.5 billion in life science companies, including investing $2.4 billion in over 80 transactions since joining the SLR platform. The team’s industry experience, strong track record, and focus on relationships with VCs, CEOs and CFOs has enabled them to successfully differentiate themselves from other lenders in the space.

Later stage drug and medical device development, diagnostic, healthcare IT, healthcare services companies with:

Multi-product pipeline / platform / disruptive technologies

Strong institutional / strategic investor support

Broad and protected intellectual property position

Experienced management and board